eTumorMetrics software improves accuracy, efficiency, and analytics in clinical trials and clinical care.
eMASS™ is advanced tumor imaging software that is used to evaluate CT and MR images and perform computer-assisted tumor-response evaluation.
Walks the reader through tumor response
Conforms to the rules of any tumor response criteria
Eliminates multiple sources of errors
Utilizes artificial intelligence to assist with tumor measurements
Reduces inter-observer variability
Captures a variety of quantitative imaging biomarkers
Provides longitudinal tables and graphical reports for the oncologic provider and the patient.
A commercial version of eMASS™ is under development and will undergo testing in preparation for FDA 510(k) clearance in 2019.
The Problem: In oncologic clinical trials, assessment of tumor response is difficult and requires multiple detailed steps and extensive documentation that must adhere to strict criteria and FDA regulations.
The Solution: eMASS™ is advanced image processing software designed to improve tumor response evaluation in clinical trials and clinical practice. Applicable to all solid tumors and lymphoma, eMASS™ improves image assessment efficiency and accuracy, a benefit to the oncologist and patient.
How does it work? eMASS™ walks the radiologist through tumor response assessment. Errors are identified in real time and corrected before moving to the next step.
Multiple steps are automated to reduce errors and improve efficiency. All tumor metrics are automatically extracted from the images and recorded. All calculations and tumor response are automated. A summary report containing key images, graphs, and tables with quantitative tumor metrics is instantly generated for display to the oncologist and patient.
What can eMASS™ measure? eMASS™ automatically extracts tumor metrics from regions of interest placed by our expert radiologists. More specifically, eMASS™ measures tumor length (long and short axis), area, mean attenuation, the vascular tumor Burden (VTB = amount of vascularized tumor), necrotic tumor burden (NTB = amount of necrotic tumor), and a wide variety of CT histogram and texture parameters. And yes, we can also measure tumor volume with eMASS™.
What is unique about eMASS™? eMASS™ does more than just reduce errors, improve efficiency, and provide longitudinal data. We have found new ways to improve inter-observer agreement and have developed a validated new quantitative imaging biomarkers, such as the vascular tumor burden (VTB) and necrotic tumor burden (NTB).
We are also incorporating artificial intelligence (machine learning) into eMASS™.
Is eMASS™ validated? eMASS™ is the only computer-assisted tumor response evaluation (CARE) software algorithm that has been validated in a multi-institutional comparative effectiveness study.